LSBCF (LakeShore Biopharma Co) Debt-to-Equity: 0.83 (As of Mar. 2025)


What is LakeShore Biopharma Co Debt-to-Equity?

LakeShore Biopharma Co LSBCF Debt-to-Equity is 0.83 as of Mar. 2025.

LakeShore Biopharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $53.92 Mil. LakeShore Biopharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $3.24 Mil. LakeShore Biopharma Co's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $68.94 Mil. LakeShore Biopharma Co's debt to equity for the quarter that ended in Mar. 2025 was 0.83.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for LakeShore Biopharma Co's Debt-to-Equity or its related term are showing as below:

LSBCF's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

LakeShore Biopharma Co  (OTCPK:LSBCF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

LakeShore Biopharma Co Debt-to-Equity Related Terms

LakeShore Biopharma Co Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Debt-to-Equity Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Debt-to-Equity
-0.04 -0.54 0.69 0.73 0.83

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only 0.69 1.00 0.73 0.61 0.83

LSBCF vs ACUT, PPCB, ENSC: Debt-to-Equity Comparison

For the Biotechnology subindustry, LakeShore Biopharma Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LakeShore Biopharma Co Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's Debt-to-Equity falls into.


LakeShore Biopharma Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

LakeShore Biopharma Co's Debt to Equity Ratio for the fiscal year that ended in Mar. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(53.922 + 3.242) / 68.938
=0.83

LakeShore Biopharma Co's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(53.922 + 3.242) / 68.938
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.83 mean?
LakeShore Biopharma Co (LSBCF) has a Debt-to-Equity of 0.83 as of Mar. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on LakeShore Biopharma Co and its competitors.
Is LakeShore Biopharma Co's Debt-to-Equity too high?
LakeShore Biopharma Co's current Debt-to-Equity is 0.83. The Biotechnology industry median Debt-to-Equity is 0.16. LakeShore Biopharma Co's value of 0.83 is 418.8% above this industry median.
How does LakeShore Biopharma Co's Debt-to-Equity compare to ACUT and PPCB?
LakeShore Biopharma Co's Debt-to-Equity of 0.83 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. LakeShore Biopharma Co's value of 0.83 is 418.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LakeShore Biopharma Co's current Debt-to-Equity of 0.83 is 418.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on LakeShore Biopharma Co and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LakeShore Biopharma Co's current Debt-to-Equity is 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Debt-to-Equity of 0.83. The current Debt-to-Equity is 0.83 and 418.8% above the Biotechnology industry median of 0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Debt-to-Equity is 0.83 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.